Drug Search Results
More Filters [+]

GPX-100

Alternative Names: gpx-100, gpx100, gpx 100
Latest Update: 2013-04-23
Latest Update Note: Clinical Trial Update

Product Description

an anthracycline similar to doxorubicin. For metastatic breast cancer. GPX-100 is unique among anthracyclines because it is not converted to doxorubicinol during metabolism in the body. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00123877)

Mechanisms of Action: TOP2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Gem
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GPX-100

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Breast Cancer

Phase 1: Anal Cancer|Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

GPX-100-003

P2

Terminated

Breast Cancer

None

CDR0000066409

P1

Completed

Anal Cancer|Breast Cancer

None

Recent News Events

Date

Type

Title